Improving Survival in Younger Patients With Waldenström Macroglobulinemia
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.